Aktuella utlysningar, vecka 7, 2019

Publicerat 2019-02-12 15:08. Uppdaterat 2019-03-06 15:49This page in English

Grants Office tipsar om aktuella utlysningar

Svenska och nordiska utlysningar

Utlysning av forskningsmedel – Försäkringskassan

Syftet med utlysningen är att utveckla kunskapen om socialförsäkringen och dess funktion för individ och samhälle. Ett ytterligare syfte är att stödja implementering av forskningsbaserade insatser inom socialförsäkringsområdet. Vi ser gärna ansökningar med ett uttalat mångfalds-, jämlikhets- och jämställdhetsperspektiv samt med tvärvetenskaplig ansats. Projektbidrag kan sökas för 1-3 år.

Closing date: 28 February 2019

Utlysning av forskningsmedel – Försäkringskassan 

Forskningsstöd – Dr P Håkansson Foundation

Dr Per Håkanssons Stiftelse inbjuder ansökningar om forskningsstöd. Dessa stöder disputerade forskare som utmärker sig inom områdena medicinsk kemi, fysiologi och livsmedelskemi. Prioritet ges till projekt inom områden där kosten är av betydelse för prevention eller behandling, och avgränsade projekt, för vilkas genomförande erhållandet av forskningsstöden är av stor betydelse, ges särskild prioritet. Stöd ges företrädesvis till yngre forskare eller disputerade forskare i tidig karriär. Sökande måste vara verksamma inom livsmedel och hälsa vid svenska universitet. Den totala budgeten är SEK 3.2 miljoner. Projekt kan rekommenderas för tvååriga anslag.

Closing date: 28 February 2019

Forskningsstöd – Dr P Håkansson Foundation 

Forskningsbidrag – Hjärnfonden

Hjärnfondens forskningsbidrag uppgår till minst 600 000 kronor och delas ut för ett eller två år. Alla områden inom Hjärnfondens verksamhetsområde kan komma ifråga för stöd.  

Closing date: 1 March 2019

Forskningsbidrag – Hjärnfonden 

Forskningsbidrag – Jane och Dan Olssons Stiftelse för Vetenskapliga Ändamål

Jane och Dan Olssons Stiftelse för Vetenskapliga Ändamål inbjuder ansökningar om forskningsbidrag. Dessa syftar till att: främja medicinsk vetenskaplig forskning i Sverige eller utomlands rörande barnlöshet och barns hälsa; främja vetenskaplig forskning rörande sociala och allmännyttiga frågor, som till exempel forskning för jämlikhet och integration i samhället och forskning som ökar ungdomars möjlighet till utbildning, framtid och livskvalitet; främja vetenskaplig forskning som verkar mot kvinnovåld, rasism, fattigdom och diskriminering i Sverige eller utomlands. Disputerade forskare och ansökningar från större forskargrupper är prioriterade.

Closing date: 1 March 2019

Forskningsbidrag – Jane och Dan Olssons Stiftelse för Vetenskapliga Ändamål 

Travel grants for doctoral students – The Swedish Society for Medical Research (SSMF)

Registered PhD students who have co-authored and published at least one peer-reviewed article are eligible to apply. Travel may begin no earlier than one month after the application deadline. The travel grants are intended to cover added personal expenses incurred during a trip to another institute or clinic for studies that will advance the applicant’s own research project. Grants are awarded for travel to learn new techniques, to gather research data, or for similar purposes. A personal invitation from the host institution and a certificate from the applicant’s main supervisor must be appended. The maximum grant is 50 000 SEK and may be awarded at most 3 times.

Closing date:  1 March 2019

Travel grants for doctoral students – The Swedish Society for Medical Research (SSMF) 

Forskningsanslag – Agneta Prytz-Folkes och Gösta Folkes stiftelse

Agneta Prytz-Folkes och Gösta Folkes stiftelse inbjuder ansökningar om forskningsanslag. Dessa stöder forskning kring ålderssjukdomar och Alzheimers sjukdom och därmed sammanhängande verksamhet. Årets ansökningar vänder sig främst till forskning inom inom medicin

Closing date: 1 March 2019

Forskningsanslag – Agneta Prytz-Folkes och Gösta Folkes stiftelse

Mixed methods: development of innovative methods in the Humanities and Social Sciences – Riksbankens Jubileumsfond

This call for proposals aims at research that develop or applies innovative methods and projects with meta-oriented perspectives. The call aims at improving researcher´s opportunities for critically analysing and using the new types of data and methods that digitization results in and challenging established methodologies and scholarly paradigms. The development of new methods can be relevant for researchers regardless of if they work with small or large data sets.

Closing date: 15 March 2019

Mixed methods: development of innovative methods in the Humanities and Social Sciences – Riksbankens Jubileumsfond 

Klinisk postdoktor – Karolinska Institutet och Region Stockholm

Detta ger stöd motsvarande halvtid till nydisputerade kliniskt verksamma personer i kombination med klinisk tjänstgöring på minst 30 procent, i syfte att stärka och förnya den kliniskt inriktade medicinska forskningen som förbättrar och utvecklar hälso- och sjukvården. Stöd uppgår till SEK 500,000 per forskare och år, i två år med möjlighet till förlängning i ytterligare två år.

Closing date: 18 March 2019

Klinisk postdoktor – Karolinska Institutet och Region Stockholm 

Exploratory pre-seed grants – Novo Nordisk Foundation

These support application-oriented research and the testing of new ideas that may lead to the development of new medical treatments, disease prevention, devices and diagnostic methods as well as the development of novel technologies within the health sciences. Grants are worth up to DKK 500,000 over four to 12 months.

Closing date: 3 April 2019

Exploratory pre-seed grants – Novo Nordisk Foundation 

Forskningsbidrag för Alzheimers sjukdom – Hjärnfonden

Tack vare att Hjärnfonden har fått flera stora gåvor och ett exceptionellt stort testamente märkt Alzheimer sjukdom, kan vi i år göra en extra utlysning till forskning om Alzheimers sjukdom. Den nya utlysningen kan ge mellan 1-3 miljoner kr per år under tre år med möjlighet till ytterligare 2 års förlängning. Alzheimerbidraget ger möjlighet till extra utdelning av medel till såväl grund- och preklinisk forskning, translationell och klinisk forskning samt vård- och omsorgsforskning. 

Closing date: 10 April 2019

Forskningsbidrag för Alzheimers sjukdom – Hjärnfonden 

Europeiska utlysningar

Research grants - Velux Foundation

The Velux Foundation invites applications for its research grants. These support innovative projects addressing the effects of daylight on humans and nature, healthy ageing or ophthalmology research. Basic or applied research projects are eligible. Applicants must be permanent employees of a university or other permanent research entity. Grants are worth between CHF 50,000 and CHF 100,000 each per year for between one and four years.

Closing date: 30 April 2019

Research grants - Velux Foundation 

Research grant in hypertension – Servier and other funders

Servier, in collaboration with the European Society of Hypertension, invites applications for its research grant in hypertension. This supports a research project in the field of hypertension and related diseases with a focus on end-organ damage, surrogate markers and biomarkers. PhD or MD graduates below the age of 45 on 1 July in the year of the award may apply. The grant is worth €30,000.

Closing date: 20 April 2019

Research grant in hypertension – Servier and other funders 

Future leaders mentorship programme for clinical diabetologists - European Association for the Study of Diabetes

The European Foundation for the Study of Diabetes, with support from AstraZeneca, invites applications for its future leaders mentorship programme for clinical diabetologists. This aims to identify and promote the advancement of the next generation of leading clinical diabetologists in Europe. Awards are worth USD 25,000 each per year over up to three years.

Closing date: 15 April 2019

Future leaders mentorship programme for clinical diabetologists - European Association for the Study of Diabetes 

Better health and care, economic growth and sustainable health systems - Horizon 2020: Societal Challenges

The European Commission Horizon 2020: Societal challenges, under the health, demographic change and wellbeing work programme, invites proposals for its H2020-SC1-BHC-2019 call. This supports projects that reconcile better health and healthy ageing with the need to develop sustainable health and care systems and growth opportunities for the health and care related industries.

Closing date: 16 Apr 2019 (Single stage)

SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications

SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health

SC1-BHC-31-2019: Pilot actions to build the foundations of a human cell atlas

SC1-BHC-32-2019: Towards a next generation influenza vaccine to protect citizens worldwide – an EU-India collaboration

SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine

SC1-HCO-15-2019: Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

Digital transformation in health and care - Horizon 2020: Societal Challenge

The European Commission Horizon 2020: Societal challenges, under the health, demographic change and wellbeing work programme, invites proposals for its H2020-SC1-DTH-2019 call. This supports projects that manage health and wellbeing while empowering the participation of citizens and facilitating the transformation of health and care services to more digitised, person-centred and community-based care models, thereby enabling better access to healthcare and the sustainability of health and care systems.

Closing date: 24 April 2019 (Single stage)

SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment

SC1-DTH-09-2019: Scaling up the univocal Identification of Medicinal Products

SC1-DTH-11-2019: Large Scale pilots of personalised & outcome based integrated care

SC1-HCC-02-2019: Support for the large scale uptake of open service platforms in the Active and Healthy Ageing domain

Amerikanska utlysningar

Federal Funding agencies

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed): NIH

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Closing date: March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. 

Funding Opportunity Announcement (FOA): RFA-CA-19-021

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed): NIH 

Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional): NIH

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.

Closing date: March 7, 2019; November 25, 2019; March 12, 2020 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-NS-18-041

Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional): NIH 

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional): NIH

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.  

Closing date: March 11, 2019; July 9, 2019; November 12, 2019; March 11, 2020; July 9, 2020; November 12, 2020; March 11, 2021; July 9, 2021; and November 12, 2021, by 5:00 PM local time of applicant organization. 

Funding Opportunity Announcement (FOA): PAR-19-070

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional): NIH 

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed): NIH

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Closing date: March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. 

Funding Opportunity Announcement (FOA): RFA-CA-19-019

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed): NIH 

Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional): NIH

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice. 

Closing date: March 7, 2019; November 25, 2019; March 12, 2020 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-NS-18-046

Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional): NIH 

 

Foundation

Berman/Topper HD Career Development Fellowship, Huntington’s Disease Society of America (HDSA), US

HDSA is committed to sponsoring innovative lines of scientific inquiry into HD biology by young researchers with a desire in making HD part of their career plan. The goal of this new program is to develop the next generation of passionate and innovative HD scientists. HDSA is proud to announce the 2018 request for proposals for this unique program. This is a three year grant mechanism to provide support for young scientists to work collaboratively with their mentors and other committed HD health professionals to help develop the fellow into an independent HD leader. Awards up to $80,000/year ($75,000 salary and research support, plus $5,000 travel/education budget)

Closing date: March 8, 2019, at 5:00 pm (EDT).

Berman/Topper HD Career Development Fellowship, Huntington’s Disease Society of America (HDSA), US 

Treatment trials for schizophrenia and bipolar disorder, Stanley Medical Research Institute, US

The largest program at SMRI is for the identification of medications that will improve the treatment of schizophrenia and bipolar disorder. The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. At any given time, SMRI is supporting 50-60 treatment trials, the majority of which are generic and/or off-label medications.

Closing date: 15 March 19 (Forecast)

Treatment trials for schizophrenia and bipolar disorder, Stanley Medical Research Institute, US 

William E Paul distinguished innovator awards in lupus and autoimmunity, Lupus Research Alliance, US

These support novel research into the fundamental causes of lupus to provide new directions toward a cure. Novel, hypothesis or discovery-driven proposals in human or animal-model based lupus research are welcome. Proposals must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a potential cure, prevention or highly effective therapy. Continuations of long-term research projects are not eligible. Awards are worth up to USD 250,000 each per year for up to four years.

Closing date: 15 March, 2019.

William E Paul distinguished innovator awards in lupus and autoimmunity, Lupus Research Alliance, US 

Länkar